The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
Gwo-Yaw HoCassandra J VandenbergRatana LimElizabeth L ChristieDale W GarsedElizabeth LieschkeKsenija NesicOlga KondrashovaGayanie RatnayakeMarc RadkeJocelyn S PeningtonAmandine CarmagnacValerie HeongElizabeth L KyranFan ZhangNadia Traficantenull nullRuby HuangAlexander DobrovicElizabeth M SwisherOrla McNallyDamien KeeMatthew J WakefieldAnthony T PapenfussDavid D L BowtellHolly E BarkerClare L ScottPublished in: Therapeutic advances in medical oncology (2023)
The efficacy observed for eribulin in PRR HGSC PDX was similar to that observed for paclitaxel, which transformed ovarian cancer clinical practice. Eribulin is therefore worthy of further consideration in clinical trials, particularly in ovarian carcinoma with early failure of carboplatin/paclitaxel chemotherapy.